Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial

Zhong, WZ; Wang, Q; Mao, WM; Xu, ST; Wu, L; Wei, YC; Liu, YY; Chen, C; Cheng, Y; Yin, R; Yang, F; Ren, SX; Li, XF; Li, J; Huang, C; Liu, ZD; Xu, S; Chen, KN; Xu, SD; Liu, LX; Yu, P; Wang, BH; Ma, HT; Yang, JJ; Yan, HH; Yang, XN; Liu, SY; Zhou, Q; Wu, YL

Wu, YL (corresponding author), Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangzhou 510080, Peoples R China.; Wu, YL (corresponding author), Guangdong Acad Med Sci, Guangzhou 510080, Peoples R China.

JOURNAL OF CLINICAL ONCOLOGY, 2021; 39 (7): 713

Abstract

PURPOSE ADJUVANT-CTONG1104 (ClinicalTrials.gov identifier: NCT01405079), a randomized phase III trial, showed that adjuvant gefitinib treatment signif......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索